Bizily Scott 4

What Happened

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics (FDMT), was granted a stock option award for 217,000 underlying shares on March 25, 2026. The Form 4 reports the derivative acquisition (code A) at $0.00—this is an option award (not an open‑market purchase or sale) and does not represent an immediate cash outlay or sale of shares.

Key Details

• Transaction date: 2026-03-25; Form 4 filed 2026-03-27 (appears timely).
• Transaction type/code: Award/Grant (A) of a derivative security (stock option).
• Shares/units: 217,000 underlying shares subject to the option. Reported price: $0.00 (no immediate purchase price disclosed).
• Vesting: Options vest 1/48th monthly beginning March 25, 2026; fully vested on the fourth anniversary if Bizily remains a service provider (i.e., fully vested March 25, 2030).
• Shares owned after transaction: Not specified in the provided filing details.
• No indication of a cashless exercise or immediate sale; these are future rights to acquire shares as they vest.

Context

This is a compensation-related option grant to an executive, which is common and intended to align long‑term incentives with shareholder value. Because it’s a derivative award (options) rather than a purchase or sale, its eventual value depends on 4D Molecular’s future stock price and any exercise terms (exercise price not shown in the provided data).